AR107281A1 - PROLONGED CONJUGATE OF THE TRIGONAL GLUCAGON RECEIVER AGONIST / GLP-1 / GIP - Google Patents
PROLONGED CONJUGATE OF THE TRIGONAL GLUCAGON RECEIVER AGONIST / GLP-1 / GIPInfo
- Publication number
- AR107281A1 AR107281A1 ARP170100003A ARP170100003A AR107281A1 AR 107281 A1 AR107281 A1 AR 107281A1 AR P170100003 A ARP170100003 A AR P170100003A AR P170100003 A ARP170100003 A AR P170100003A AR 107281 A1 AR107281 A1 AR 107281A1
- Authority
- AR
- Argentina
- Prior art keywords
- conjugate
- gip
- glp
- prolonged
- glucagon
- Prior art date
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Reivindicación 1: Un conjugado representado por la fórmula química (1) a continuación: X-Lₐ-F (1) en la que, X es un péptido que tiene acciones en un receptor del glucagón, un péptido similar al glucagón tipo 1 (GLP-1) y un receptor polipéptido insulinotrópico dependiente de la glucosa (GIP); L es un conector; a es 0 o un entero positivo, con la condición que cuando a es 2 o mayor, cada L es independiente una de otra; y F es un material que puede aumentar la vida media de X. Reivindicación 23: Una composición farmacéutica para prevenir o tratar el síndrome metabólico que comprende un conjugado según cualquiera de las reivindicaciones 1 a 13. Reivindicación 24: La composición farmacéutica de la reivindicación 23, en la que el síndrome metabólico comprende intolerancia a la glucosa, hipercolesterolemia, dislipidemia, obesidad, diabetes, hipertensión, arteriosclerosis debido a la dislipidemia, ateroesclerosis, arteriosclerosis, o cardiopatía coronaria.Claim 1: A conjugate represented by the chemical formula (1) below: X-Lₐ-F (1) wherein, X is a peptide having actions at a glucagon receptor, a glucagon-like peptide type 1 (GLP) -1) and a glucose-dependent insulinotropic polypeptide receptor (GIP); L is a connector; a is 0 or a positive integer, with the proviso that when a is 2 or greater, each L is independent of each other; and F is a material that can increase the half-life of X. Claim 23: A pharmaceutical composition for preventing or treating metabolic syndrome comprising a conjugate according to any of claims 1 to 13. Claim 24: The pharmaceutical composition of claim 23 , in which the metabolic syndrome comprises glucose intolerance, hypercholesterolemia, dyslipidemia, obesity, diabetes, hypertension, arteriosclerosis due to dyslipidemia, atherosclerosis, arteriosclerosis, or coronary heart disease.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20150191082 | 2015-12-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR107281A1 true AR107281A1 (en) | 2018-04-18 |
Family
ID=62104015
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP170100004A AR107282A1 (en) | 2015-12-31 | 2017-01-02 | TRIPLE AGONIST THAT HAS ACTIVITY FOR A GLUCAGON RECEIVER, A GLUCAGON PEPTIDE 1 RECEIVER (GLP-1) AND A GLUCOSE DEPENDENT INSULINOTROPIC PEPTIDE RECEPTOR (GIP) |
ARP170100003A AR107281A1 (en) | 2015-12-31 | 2017-01-02 | PROLONGED CONJUGATE OF THE TRIGONAL GLUCAGON RECEIVER AGONIST / GLP-1 / GIP |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP170100004A AR107282A1 (en) | 2015-12-31 | 2017-01-02 | TRIPLE AGONIST THAT HAS ACTIVITY FOR A GLUCAGON RECEIVER, A GLUCAGON PEPTIDE 1 RECEIVER (GLP-1) AND A GLUCOSE DEPENDENT INSULINOTROPIC PEPTIDE RECEPTOR (GIP) |
Country Status (3)
Country | Link |
---|---|
AR (2) | AR107282A1 (en) |
MA (4) | MA42891B2 (en) |
MY (1) | MY199261A (en) |
-
2016
- 2016-12-30 MA MA42891A patent/MA42891B2/en unknown
- 2016-12-30 MY MYPI2018001199A patent/MY199261A/en unknown
- 2016-12-30 MA MA42889A patent/MA42889B2/en unknown
- 2016-12-30 MA MA51955A patent/MA51955B1/en unknown
-
2017
- 2017-01-02 AR ARP170100004A patent/AR107282A1/en unknown
- 2017-01-02 AR ARP170100003A patent/AR107281A1/en unknown
-
2018
- 2018-07-26 MA MA53533A patent/MA53533A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
MA53533A1 (en) | 2022-08-31 |
MA42891B2 (en) | 2021-11-30 |
AR107282A1 (en) | 2018-04-18 |
MY199261A (en) | 2023-10-23 |
MA51955A1 (en) | 2021-10-29 |
MA42889B2 (en) | 2020-11-30 |
MA51955B1 (en) | 2022-04-29 |
MA42891A1 (en) | 2019-04-30 |
MA42889A1 (en) | 2018-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20181494A1 (en) | PERSISTENT CONJUGATE OF TRIPLE ACTIVATOR THAT ACTIVATES THE GLUCAGON RECEPTOR, GLP-1 U GIP | |
EA202090392A3 (en) | GIP AND GLP-1 COAGONIST COMPOUNDS | |
DOP2021000273A (en) | GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS | |
CY1121423T1 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF A METABOLIC SYNDROME | |
PE20210162A1 (en) | INCRETINE ANALOGS AND THEIR USES | |
PE20211637A1 (en) | GIP / GLP1 COAGONISTS COMPOUNDS | |
EA202091284A1 (en) | INCRETIN ANALOGUES AND THEIR APPLICATION | |
BR112019011228A2 (en) | compounds as peptide trigonal glp1 / glucagon / gip receptor agonists | |
MX2016015182A (en) | Antidiabetic tricyclic compounds. | |
MX2015010935A (en) | Antidiabetic bicyclic compounds. | |
BRPI0924307B8 (en) | oxyntomodulin analogues | |
MX2019006427A (en) | New compounds as peptidic glp1/glucagon/gip receptor agonists. | |
EA201890417A1 (en) | GENETICALLY CODED, INTERNALLY DISORDERED "INVISIBLE" POLYMERES FOR DELIVERY AND THEIR APPLICATION METHODS | |
PH12015502547A1 (en) | Anti-glucagon receptor antibodies and methods of use thereof | |
PE20220938A1 (en) | GIPR AGONIST COMPOUNDS | |
PE20171622A1 (en) | INSULIN GLARGIN / LIXISENATIDE FIXED RATIO FORMULATION | |
EA202191379A1 (en) | COMBINED NAFLD AND NASH TREATMENT | |
DOP2022000122A (en) | INCRETIN ANALOGS AND THEIR USES | |
AR107281A1 (en) | PROLONGED CONJUGATE OF THE TRIGONAL GLUCAGON RECEIVER AGONIST / GLP-1 / GIP | |
BR112015003916A2 (en) | peptide selected from the group consisting of peptide glp-1, peptide gip and their dipeptidyl peptidase iv (dpp-iv) resistant analogs; and pharmaceutical composition | |
EA202092891A1 (en) | GIP / GLP1 COAGONISTS | |
MX2021007124A (en) | Pharmaceutical composition containing insulin and glucagon. | |
TH172514A (en) | Compounds work together GIP and GLP-1. | |
三村俊哉 | Dipeptidyl peptidase-4 inhibitor anagliptin facilitates restoration of dextran sulfate sodium-induced colitis | |
EA201791296A1 (en) | COMPOSITION WITH CONTINUOUS RELATIONSHIP INSULIN GLARGIN / LIKSENENID |